65. Yamano Y, Ohyama K, Kikyo M, Sano T, Nakagomi Y, et al. (1995) Mutagenesis and the molecular modeling of the rat angiotensin II receptor (AT1). J Biol Chem 270: 14024–14030. 66. Leong SR, Kabakoff RC, Hebert CA (1994) Complete mutagenesis of the extracellular domain of interleukin-8 (IL-8) type A receptor identifies charged residues mediating IL-8 binding and signal transduction. J Biol Chem 269: 19343–19348. 67. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, et al. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330: 1066–1071. 68. Kufareva I, Rueda M, Katritch V, Stevens RC, Abagyan R (2011) Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. Structure 19: 1108–1126. 69. Michino M, Abola E, Brooks CL 3rd, Dixon JS, Moult J, et al. (2009) Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nat Rev Drug Discov 8: 455–463. 70. Senderowitz H, Marantz Y (2009) G Protein-Coupled Receptors: target-based in silico screening. Curr Pharm Des 15: 4049–4068. 71. Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, et al. (2011) Structure of the human histamine H1 receptor complex with doxepin. Nature 475: 65–70. 72. Totrov M, Abagyan R (2008) Flexible ligand docking to multiple receptor conformations: a practical alternative. Curr Opin Struct Biol 18: 178–184. 73. Novoa EM, Ribas de Pouplana L, Barril X, Orozco M (2010) Ensemble Docking from Homology Models. Journal of Chemical Theory and Computa- tion 6: 2547–2557. 74. Carlsson J, Coleman RG, Setola V, Irwin JJ, Fan H, et al. (2011) Ligand discovery from a dopamine D(3) receptor homology model and crystal structure. Nat Chem Biol. 75. Vilar S, Ferino G, Phatak SS, Berk B, Cavasotto CN, et al. (2011) Docking- based virtual screening for ligands of G protein-coupled receptors: not only crystal structures but also in silico models. J Mol Graph Model 29: 614–623. 76. Phatak SS, Gatica EA, Cavasotto CN (2010) Ligand-steered modeling and docking: A benchmarking study in class A G-protein-coupled receptors. J Chem Inf Model 50: 2119–2128. Small-Molecule Binders of Prokineticin Receptors 77. Bohm H-J, Flohr A, Stahl M (2004) Scaffold hopping. Drug Discovery Today: Technologies 1: 217–224. 78. Boyd M (2007) Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? Expert Opin Pharmacother 8: 957–964. 79. De Clercq E (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33: 307–320. 80. Holmberg SD, Moorman AC, Greenberg AE (2004) Trends in rates of myocardial infarction among patients with HIV. N Engl J Med 350: 730-732; author reply 730-732. 81. Shankar SS, Dube MP, Gorski JC, Klaunig JE, Steinberg HO (2005) Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 150: 933. 82. Eira M, Araujo M, Seguro AC (2006) Urinary NO3 excretion and renal failure in indinavir-treated patients. Braz J Med Biol Res 39: 1065–1070. 83. Wang X, Chai H, Lin PH, Yao Q, Chen C (2009) Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti- human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol 174: 771–781. 84. Hoogerwerf WA (2006) Prokineticin 1 inhibits spontaneous giant contractions in the murine proximal colon through nitric oxide release. Neurogastroenterol Motil 18: 455–463. 85. Lazareno S, Popham A, Birdsall NJ (2000) Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Mol Pharmacol 58: 194–207. 86. Allen JA, Roth BL (2011) Strategies to discover unexpected targets for drugs active at g protein-coupled receptors. Annu Rev Pharmacol Toxicol 51: 117–144. 87. Tobin AB, Butcher AJ, Kong KC (2008) Location, location, location…site- specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling. Trends Pharmacol Sci 29: 413–420. 88. Ryu GM, Song P, Kim KW, Oh KS, Park KJ, et al. (2009) Genome-wide analysis to predict protein sequence variations that change phosphorylation sites or their corresponding kinases. Nucleic Acids Res 37: 1297–1307. PLoS ONE | www.plosone.org 17 November 2011 | Volume 6 | Issue 11 | e27990